/
Oncology
Acute Leukemia
56
Pipeline Programs↗
52
Active Trials↗
36
Companies Involved↗
Acute Leukemia is a moderately active landscape with 56 programs across 36 companies. The most active players are Sumitomo Pharma America, Inc., Johnson & Johnson, Institut de Recherches Internationales Servier (I.R.I.S.). 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 18
Phase 234
Phase 34
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
42 of 52 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 96% of 56 pipeline programs.
Analysis
Trial Status
167
clinical trials
Completed58 · 35%
Recruiting29 · 17%
Unknown status25 · 15%
Terminated22 · 13%
Active, not recruiting11 · 7%
Not yet recruiting11 · 7%
Other11 · 7%
Clinical Trials
Trial Activity
167 trials
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Recruiting·—·Phase 1·NCT06575296·27 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)